Catalyst Wire Dossier Catalyst Wire Dossier

AZD8186

PI3K-beta inhibitor · AstraZeneca
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for AZD8186, covering 2019-06-28 to 2023-09-21. Get the full timeline:

Most recent: Clinical Trial Update: PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]

See pricing